ANN ARBOR — Rubicon Genomics Inc. said Thursday it had signed a supply agreement with Durham, N.C.-based Kreatech Diagnostics for the use of its whole genome amplification technology.
Under the agreement, Rubicon will supply proprietary reagents incorporating parts of its OmniPlex amplification technology to Kreatech for use in the manufacturing of Kreatech’s Poseidon fluorescence in situ hybridization probes.
“This new agreement further demonstrates the broad applicability of our suite of pre-analytical amplification technologies for producing superior results in nucleic acid detection and analysis,” said Rubicon CEO James Koziarz. “By incorporating key elements of our technology into their manufacturing process, Kreatech is able to enhance the reliability, efficiency and reproducibility of production of their FISH probes.”
Added Herman Volkers, COO of Kreatech: “Kreatech’s Poseidon Repeat-Free technology eliminates repetitive elements in DNA FISH probes and in combination with our unique proprietary labeling technology … delivers results that have less background, more specificity and a brighter signal. Use of Rubicon’s proprietary pre-analytical amplification reagents during the production process contributes to achievement of this superior performance.”
Kreatech’s products enable customers to detect genetic aberrations that may lead to cancer or other diseases.
Rubicon’s OmniPlex family of amplification technologies are designed to deliver sufficient quantities of high quality species-specific or locus-specific RNA or DNA to increase the sensitivity and specificity of analyses of biological samples for biomedical research and clinical medicine. They use proprietary methods to prepare samples for sensitive and accurate PCR, microarray and next-generation sequencing analysis, and provide exceptional consistency, superior performance and proven sensitivity.
Further terms of the agreement were not disclosed.